8721. Pregnancy outcome and family size in systemic lupus erythematosus: a case-control study.
作者: C J Hardy.;B P Palmer.;S J Morton.;K R Muir.;R J Powell.
来源: Rheumatology (Oxford). 1999年38卷6期559-63页
To establish pregnancy outcomes and family size in a geographically defined population of systemic lupus erythematosus (SLE) patients.
8722. Femoral intercondylar notch measurements in osteoarthritic knees.
We measured the dimensions of the intercondylar notch of the femur in 32 patients with primary severe osteoarthrosis (OA) of the knee and 54 embalmed cadaveric knees.
8723. Detection of mycobacteria in joint samples from patients with arthritis using a genus-specific polymerase chain reaction and sequence analysis.
作者: I M van der Heijden.;B Wilbrink.;L M Schouls.;J D van Embden.;F C Breedveld.;P P Tak.
来源: Rheumatology (Oxford). 1999年38卷6期547-53页
Mycobacteria have been implicated in the pathogenesis of various forms of arthritis. The aim of this study was to examine the diagnostic potential of molecular biological techniques as well as to investigate the pathogenetic role of mycobacteria in chronic arthritis.
8724. Concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime-labelled leucocytes and ileocolonoscopy in patients with spondyloarthropathies and without clinical evidence of inflammatory bowel disease.
作者: A El Maghraoui.;M Dougados.;E Freneaux.;S Chaussade.;B Amor.;M Breban.
来源: Rheumatology (Oxford). 1999年38卷6期543-6页
To study the concordance between abdominal scintigraphy using technetium-99m hexamethylpropylene amine oxime (99mTc-HMPAO)-labelled leucocytes (ASTLL) and ileocolonoscopy in patients with spondyloarthropathies (SpA) and without clinical evidence of inflammatory bowel disease (IBD).
8725. Development and validation of a self-administered systemic sclerosis questionnaire (SySQ).
To develop a self-administered systemic sclerosis questionnaire (SySQ) covering condition-specific functional limitation and symptoms. METHODS An initial item pool was generated by open patient interviews. A preliminary questionnaire was devised using 62 systemic sclerosis (SSc; scleroderma) patients. Factor analysis was used for further selection and grouping of items into distinct scales. The retrieved scales were tested for internal consistency and test-retest reliability. Spearman's rank correlation and Wilcoxon's rank sum test were used to examine hypothesized associations of the SySQ with various clinical and laboratory features.
8726. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement.
作者: P R Ames.;J Alves.;I Murat.;D A Isenberg.;J Nourooz-Zadeh.
来源: Rheumatology (Oxford). 1999年38卷6期529-34页
To evaluate the occurrence and clinical significance of lipid peroxidation (oxidative stress) in rheumatic diseases characterized by vascular involvement.
8727. Predicting 'normal' grip strength for rheumatoid arthritis patients.
An ability to predict accurately 'normal' grip strength in rheumatoid arthritis (RA) patients would facilitate a more accurate assessment of the degree of their functional loss. This, in turn, would allow the setting of more meaningful treatment goals aimed at restoring hand function towards normal. This study carefully measures three modalities of hand grip strength and their correlation with multiple simple anthropometric parameters in normal subjects. We aim to determine which of these parameters are best correlated to grip strength, and whether this correlation is strong enough to allow the accurate prediction of what normal grip strength should be in RA patients.
8728. Association of Fas/APO-1 gene polymorphism with systemic lupus erythematosus in Japanese.
作者: T Horiuchi.;H Nishizaka.;S Yasunaga.;M Higuchi.;H Tsukamoto.;K Hayashi.;K Nagasawa.
来源: Rheumatology (Oxford). 1999年38卷6期516-20页
This study was undertaken to investigate the possible association of Fas gene mutation(s) or polymorphism(s) with systemic lupus erythematosus (SLE) in Japanese.
8729. Measurement of matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in patients with knee osteoarthritis: comparison with generalized osteoarthritis.
作者: K Naito.;M Takahashi.;K Kushida.;M Suzuki.;T Ohishi.;M Miura.;T Inoue.;A Nagano.
来源: Rheumatology (Oxford). 1999年38卷6期510-5页
To compare plasma levels of matrix metalloproteinase (MMP)-3, MMP-9 and tissue inhibitor of metalloproteinases-1 (TIMP-1) between patients with knee osteoarthritis and normal subjects, to investigate whether the degree of knee joint involvement is related to those measurements, and to compare patients with and without generalized osteoarthritis.
8730. Detection of mycoplasmal infections in blood of patients with rheumatoid arthritis.
Mycoplasmal infections are associated with several acute and chronic illnesses. Some mycoplasmas can enter a variety of tissues and cells, and cause system-wide or systemic signs and symptoms.
8731. Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland.
作者: R Myllykangas-Luosujärvi.;K Aho.;H Kautiainen.;M Hakala.
来源: Rheumatology (Oxford). 1999年38卷6期499-503页
Virtually all studies dealing with the occurrence of amyloidosis in subjects with rheumatoid arthritis (RA) have been based on selected series collected from university clinics. The purpose of the study was to obtain information on the true prevalence of amyloidosis and the role of amyloidosis as a cause of death.
8733. Should dehydroepiandrosterone replacement therapy be provided with glucocorticoids?
Adrenocorticotrophic hormone (ACTH) induces the concomitant secretion of glucocorticoids (GC) and dehydroepiandrosterone (DHEA) from the adrenal cortex. Whereas GC are catabolic, DHEA is anabolic. Long-term GC administration may result in some deleterious side-effects, such as muscular weakness, atrophy and necrosis, diabetes, fattiness, osteopenia, osteoporosis and avascular necrosis and susceptibility to infections. DHEA ameliorates some deleterious effects of GC, such as diabetes, amino acid deamination, fattiness, hypertension and susceptibility to viraemia. By its anabolic effects in muscles, bones and endothelium, DHEA may diminish the severity of GC-induced myopathy, osteopenia, osteoporosis and avascular necrosis. The natural concomitant secretion of DHEA with GC probably enables the latter to protect the body from ill-effects of stress without exerting their deleterious potency. DHEA secretion diminishes during aging and severe or chronic diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Anti-inflammatory and immunosuppressive effects of GC and androgens, including DHEA, are now well established. On the other hand, administration of GC inhibits ACTH secretion, involutes the adrenal cortex and results in further DHEA deficiency, particularly harmful in chronic autoimmune diseases (i.e. RA, SLE). Therefore, the deleterious side-effects of chronic administration of GC emerges from both their direct catabolic activity and the suppression of DHEA production. Whereas, in males, most androgens come from the testes, in females, under GC supplementation, DHEA deficiency leads to nullification of the androgen-dependent anabolism, leaving them exposed to the GC-catabolic effects to a larger extent. The viewpoint presented here claims that under chronic GC supplementation, DHEA replacement therapy may reduce damage caused by GC administration.
|